Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

0.2075 +0.0084 (+4.22%)
Streaming Delayed Price Updated: 10:01 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CNS Pharmaceuticals to Present at the LSX World Congress 2024
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event
Via Investor Brand Network
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients
Via Investor Brand Network
Researchers Link Hormone Treatments to Heightened Risk of Brain Tumors
Via Investor Brand Network
New Research Sheds Light on the Initial Stages of Brain Cancer Development
Via Investor Brand Network
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update
Via Investor Brand Network
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Via ACCESSWIRE
CNS Pharmaceuticals to Present at Two Investor Conferences in April
Via ACCESSWIRE
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors
Via Investor Brand Network
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
Via ACCESSWIRE
Study Shows Troops That Sustain Serious Brain Injuries Have Higher Risk of Brain Cancer
Via Investor Brand Network
Scientists Start Trialing First Blood Test Against Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
Via ACCESSWIRE
Novel Brain Scan Technique Exposes Vulnerability of Gliomas
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Light, Viruses Could Transform Brain-Tumor Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification
Via Investor Brand Network
Researchers Discuss How Brain Cancer Radiotherapy Side Effects Can Be Reduced
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
Via Investor Brand Network
Topics Death
Exposures Death
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Via ACCESSWIRE
Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
Via Investor Brand Network
Topics Death
Exposures Death
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.